Troglitazone__PPARgamma agonist JTC-802
Product Name
Troglitazone
Description
PPARgamma agonist
Purity
>98%
CAS No.
97322-87-7
Molecular Formula
C24H27NO5S
Molecular Weight
441.54
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Agonist
Solubility
Soluble to 100 mM in DMSO and to 10 mM in ethanol
Source
Synthetic
Appearance
White solid
SMILES
CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
InChI
InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,
InChIKey
GXPHKUHSUJUWKP-UHFFFAOYSA-N
Safety Phrases
Classification: Harmful. May be harmful if inhaled, swallowed or absorbed through skin.
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Risk Phrases:
R20/21/22 – Harmful by inhalation, in contact with skin and if swallowed
R40 – Limited evidence of a carcinogenic effect
Cite This Product
Troglitazone (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-260)
Alternative Names
5-{4-(6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxybenzyl}-1,3-thiazolidine-2,4-dione, Rezulin
Research Areas
Cancer, Apoptosis
PubChem ID
5591
Scientific Background
Troglitazone, a member of the thaizolidinediones, is an anti-diabetic and anti-inflammatory drug. It works by activating peroxisome proliferator-activated receptors (PPARs) (1). It is a ligand to both PPARalpha and gamma. It also contains an alpha-tocopheroyl moiety, potentially giving it vitamin E like activity (which helps in inflammation) (2).
References
1. Lambe K.G. and Tugwood J.D. (1996) Eur J Biochem. 239(1): 1-7.
2. Aljada A., et al. (2001) J Clin Endocrinol Metab. 86(7): 3250-3256.
PPARgamma agonist
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Risk Phrases:
R20/21/22 – Harmful by inhalation, in contact with skin and if swallowed
R40 – Limited evidence of a carcinogenic effect
2. Aljada A., et al. (2001) J Clin Endocrinol Metab. 86(7): 3250-3256.